Evotec invests $18 million in Exscientia | October 9, 2017 Issue - Vol. 95 Issue 40 | Chemical & Engineering News
Volume 95 Issue 40 | p. 21 | Concentrates
Issue Date: October 9, 2017

Evotec invests $18 million in Exscientia

By Ryan Cross
Department: Business
Keywords: informatics, drug discovery

The German contract research firm Evotec is expanding a partnership with the AI-based drug discoverer Exscientia and acquiring an $18 million stake in the company. Evotec’s collaboration with the British firm began 18 months ago to design immuno-oncology drugs that purposefully bind two targets. Evotec CEO Werner Lanthaler liked what he saw. The new deal makes the two firms 50:50 partners on their drug discovery program, Lanthaler says, adding that it is unlikely Evotec would take a compound to the clinic alone.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment